Expand VRDN Menu
VRDN MENU

VRDN Latest Press Releases

-- June 29, 2026 --

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones Globe Newswire 9:50 AM

-- June 26, 2026 --

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease Business Wire 6:00 PM

-- May 27, 2026 --

Viridian Therapeutics to Participate in Upcoming June Investor Conferences Business Wire 7:00 AM

-- May 6, 2026 --

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million Business Wire 11:13 PM

-- May 5, 2026 --

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock Business Wire 4:05 PM
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress Business Wire 7:01 AM
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-2 Clinical Trial in Chronic Thyroid Eye Disease Business Wire 7:00 AM

-- March 31, 2026 --

Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 11:00 AM

-- March 30, 2026 --

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease Business Wire 7:03 AM

-- February 26, 2026 --

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results Business Wire 7:01 AM
Market Data Delayed 15 Minutes